Diagnosis and Staging: Genomic studies are not recommended in routine clinical practice but may be appropriate in selected patients with malignant pleural mesothelioma (MPM), especially those with young age and family history of cancer, who may carry germline mutations in cancer susceptibility … More
Main Navigation Menu
➤ Find Out Who Was Exposed to Asbestos and How
➤ North Carolina Asbestos Exposure Work / Job Sites
➤ Asbestos-Contaminated Talc Mesothelioma Lawsuits
➤ Mesothelioma / Lung Cancer / Asbestosis: Basic Facts
➤ How to Get Legal Compensation for Your Case
➤ Case Evaluation — Free. Confidential. No Obligation.
➤ Questions New Clients Have Asked Us (FAQs)
➤ Information About Our Law Firm
➤ Asbestos Attorney Tom Lamb
➤ Collection of News and Reports
You can use our Quick Contact Form to tell us about your case.
Recent News & Reports
Study seeks to identify biological markers that predict mesothelioma response to treatment
The National Cancer Institute (NCI) has granted a $2.5 million, five-year R37 MERIT Award to Dr. Bryan Burt, associate professor of surgery and chief of the Division of General Thoracic Surgery, for his research project titled, “Proteomic Determinants of Response to Checkpoint Blockade in Malignant … More
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Background: Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy regimens that have moderate survival benefit with poor outcomes. Nivolumab plus ipilimumab has shown clinical benefit in other tumour types, including first-line non-small-cell lung … More
New Options Spark Sequencing and Biomarker Trials in Mesothelioma
Now that a new standard of care has been established in frontline mesothelioma, clinical trials are needed to evaluate optimal sequencing with checkpoint inhibitors in the salvage setting and determine whether biomarkers of response to immunotherapy could further tailor treatment to individual … More
Bristol’s Opdivo scores again in tough-to-treat mesothelioma, this time flying solo
Last year at the World Conference on Lung Cancer, Bristol Myers Squibb made waves in mesothelioma with data showing its Opdivo - Yervoy duo could slash the risk of death in previously untreated patients. This year, it grabbed the spotlight with another survival win in the tough-to-treat … More
Cell and extracellular matrix interaction models in benign mesothelial and malignant pleural mesothelioma cells in 2D and 3D in‐vitro
Malignant pleural mesothelioma (MPM) is an aggressive tumour that grows in the pleural cavity. [ Malignant pleural mesothelioma (MPM) ] spheroids released in the pleural fluid can form new tumour foci. Cell–cell, cell–extracellular matrix (ECM) interactions in 2D and 3D impact malignant cell … More